Evidence map›Paper›PMID 27737899›Full record

ArticleEMBO molecular medicine2016

Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality.

Lin Li, Xiaotian Qi, Weili Sun, Hisham Abdel-Azim, Siyue Lou, Hong Zhu, Nemani V Prasadarao, Alice Zhou, Hiroyuki Shimada, Koichi Shudo and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Lin LiDepartment of Pathology, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Xiaotian QiDevelopmental Biology and Regenerative Medicine Program, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Weili SunPediatric Hematology-Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Hisham Abdel-AzimPediatric Hematology-Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Siyue LouDepartment of Pathology, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Hong ZhuDepartment of Pathology, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Nemani V PrasadaraoUniversity of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Alice ZhouDepartment of Pathology, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Hiroyuki ShimadaDepartment of Pathology, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Koichi ShudoJapan Pharmaceutical Information Center, Shibuya-ku, Tokyo, Japan.
Yong-Mi KimPediatric Hematology-Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Sajad KhazalPediatric Hematology-Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Qiaojun HeInstitute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, Zhejiang, China.
David WarburtonDevelopmental Biology and Regenerative Medicine Program, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA.
Lingtao WuDepartment of Pathology, Children's Hospital Los Angeles Saban Research Institute, Los Angeles, CA, USA lwu@chla.usc.edu lwu@therapeuticapp.org.ORCID 0000-0002-8970-6952
University of Southern California · USChildren's Hospital of Los Angeles · USShibuya (Japan) · JPZhejiang University · CN

Funding

Training Physician Scientists in Pediatric OncologyT32CA009659 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI DECLERCK, YVES A · 1991 to 2020
$2.2M
CAK-RARa Signaling in HSC and Leukemic Cell Commitment to DifferentiationR01CA120512 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI WU, LINGTAO · 2008 to 2012
$1.8M
NCI NIH HHS R01 CA120512NCI NIH HHS T32 CA009659
6 · The paper itself

Abstract

Neutrophils generated by granulocyte colony-stimulating factor (GCSF) are functionally immature and, consequently, cannot effectively reduce infection and infection-related mortality in cancer chemotherapy-induced neutropenia (CCIN). Am80, a retinoic acid (RA) agonist that enhances granulocytic differentiation by selectively activating transcription factor RA receptor alpha (RARα), alternatively promotes RA-target gene expression. We found that in normal and malignant primary human hematopoietic specimens, Am80-GCSF combination coordinated proliferation with differentiation to develop complement receptor-3 (CR3)-dependent neutrophil innate immunity, through altering transcription of RA-target genes RARβ

Indexed as

AnimalsAntineoplastic AgentsBacteremiaBenzoatesCell DifferentiationCell ProliferationDisease Models, AnimalGranulocyte Colony-Stimulating FactorImmunologic FactorsMiceNeutropeniaNeutrophilsSurvival AnalysisTetrahydronaphthalenesAntineoplastic AgentsBenzoatesGranulocyte Colony-Stimulating FactorImmunologic FactorstamibaroteneTetrahydronaphthalenesfunctional neutrophilsinnate immunitymyeloid expansionneutrophil bactericidal activityneutrophil differentiation

Identifiers

PMID27737899
PMCPMC5090663
OpenAlexW2530404704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.